GLAND PHARMA
|
GLAND PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 62.35 | 42.40 | 46.90 | 47.42 | 73.75 |
| CEPS(Rs) | 88.07 | 65.33 | 67.82 | 56.33 | 80.46 |
| DPS(Rs) | 20.00 | 18.00 | 20.00 | - | - |
| Book NAV/Share(Rs) | 625.91 | 555.40 | 529.56 | 483.12 | 434.84 |
| Tax Rate(%) | 29.86 | 34.27 | 31.79 | 25.94 | 25.14 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 25.34 | 22.59 | 23.53 | 28.27 | 34.32 |
| EBIT Margin(%) | 23.29 | 19.67 | 20.46 | 29.30 | 36.90 |
| Pre Tax Margin(%) | 22.77 | 18.92 | 19.99 | 29.10 | 36.78 |
| PAT Margin (%) | 15.98 | 12.44 | 13.64 | 21.55 | 27.53 |
| Cash Profit Margin (%) | 22.56 | 19.16 | 19.72 | 25.60 | 30.04 |
| Performance Ratios | |||||
| ROA(%) | 8.70 | 6.41 | 7.97 | 9.40 | 16.91 |
| ROE(%) | 10.56 | 7.82 | 9.26 | 10.34 | 18.61 |
| ROCE(%) | 14.96 | 11.97 | 13.63 | 14.04 | 24.85 |
| Asset Turnover(x) | 0.54 | 0.52 | 0.58 | 0.44 | 0.61 |
| Sales/Fixed Asset(x) | 1.04 | 1.06 | 1.55 | 1.66 | 2.51 |
| Working Capital/Sales(x) | 1.09 | 1.08 | 1.33 | 0.59 | 0.84 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.96 | 0.95 | 0.64 | 0.60 | 0.40 |
| Receivable days | 96.72 | 99.92 | 78.29 | 97.99 | 72.40 |
| Inventory Days | 97.32 | 108.54 | 116.00 | 157.65 | 102.05 |
| Payable days | 134.60 | 138.65 | 113.80 | 113.72 | 74.34 |
| Valuation Parameters | |||||
| PER(x) | 27.22 | 37.55 | 39.27 | 26.75 | 44.33 |
| PCE(x) | 19.27 | 24.37 | 27.16 | 22.52 | 40.63 |
| Price/Book(x) | 2.71 | 2.87 | 3.48 | 2.63 | 7.52 |
| Yield(%) | 1.18 | 1.13 | 1.09 | - | - |
| EV/Net Sales(x) | 3.86 | 4.26 | 5.09 | 4.73 | 11.50 |
| EV/Core EBITDA(x) | 12.77 | 16.15 | 19.17 | 13.54 | 29.19 |
| EV/EBIT(x) | 16.59 | 21.68 | 24.87 | 16.13 | 31.18 |
| EV/CE(x) | 2.34 | 2.54 | 3.19 | 2.15 | 7.07 |
| M Cap / Sales | 4.35 | 4.67 | 5.36 | 5.76 | 12.21 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 14.50 | -0.85 | 56.29 | -17.64 | 27.08 |
| Core EBITDA Growth(%) | 31.25 | -1.38 | 18.82 | -27.04 | 20.67 |
| EBIT Growth(%) | 35.59 | -4.67 | 9.11 | -34.60 | 21.34 |
| PAT Growth(%) | 47.07 | -9.57 | -1.10 | -35.54 | 21.54 |
| EPS Growth(%) | 47.07 | -9.60 | -1.10 | -35.70 | 21.01 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.02 | 0.03 | 0.04 | - | - |
| Current Ratio(x) | 4.68 | 4.33 | 4.04 | 9.46 | 10.05 |
| Quick Ratio(x) | 3.60 | 3.26 | 2.85 | 6.80 | 8.02 |
| Interest Cover(x) | 45.01 | 26.30 | 44.23 | 142.61 | 309.77 |
| Total Debt/Mcap(x) | 0.01 | 0.01 | 0.01 | - | - |
Compare Financial Ratios of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹42,525.5 Cr | 6.2% | 4.8% | 24.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,870.0 Cr | -1.4% | 2.4% | 17.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹220,946.0 Cr | 12.2% | 23.1% | 21.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹190,907.0 Cr | 2.4% | 5.3% | 41.7% | Stock Analytics | |
| CIPLA | ₹118,674.0 Cr | 1.7% | 0.7% | -3.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,648.7 Cr | 3% | -14.9% | -10.2% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | 6.2% |
4.8% |
24.3% |
| SENSEX | 2.4% |
1.5% |
-4.3% |
You may also like the below Video Courses
